onr:"swepub:oai:gup.ub.gu.se/106846"
Search: onr:"swepub:oai:gup.ub.gu.se/106846" > Impact of short-ter...
- 1 of 1
- Previous record
- Next record
- To hitlist
Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
-
- Jin, Tao, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
-
- Bokarewa, Maria, 1963 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
- Amu, Sylvie, 1978 (author)
- show more...
- show less...
- (creator_code:org_t)
- 2009
- 2009
- English.
- In: Clinical and experimental rheumatology. - 0392-856X. ; 27:3, s. 491-4
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- BACKGROUND: Imbalance of haemostasis in patients with rheumatoid arthritis (RA) contributes to future risk of cardiovascular diseases (CVD). Prothrombotic molecules, e.g. fibrinogen, D-dimer, and tPA are elevated in plasma of RA patients, being associated to CVD. There is no imformation about the influence of biological drugs, e.g. anti-CD20 and tumor necrosis factor (TNF) antibodies on these prothrombotic molecules. OBJECTIVE: To assess whether anti-TNF and anti-CD20 therapies modify the profiles of cardiovascular risk factors in patients with RA. METHODS: The expression of prothrombotic molecules in plasma was investigated in 10 RA patients before and after treatment with TNF-alpha antibodies and in another 12 RA patients before and after anti-CD20 treatment. RESULTS: Both anti-TNF and anti-CD20 infusions gave rise to clear clinical improvement. However, only anti-CD20 infusion significantly (p=0.05) reduced concentration of fibrinogen (p=0.05), D-dimer (p<0.001), as well as tPA levels (p<0.01). In contrast, in TNF antibody treated patients only tPA levels were significantly decreased following the treatment (p<0.05). CONCLUSIONS: Infusion of CD20 antibodies to the patients with active RA led to a clearly reduced plasma levels of predictors of CVD indicating that this treatment, apart from its anti-inflammatory properties, may reduce the risk for future CVD in RA.
Keyword
- Adult
- Aged
- Antibodies
- therapeutic use
- Antibodies
- Monoclonal
- therapeutic use
- Antigens
- CD20
- immunology
- Antirheumatic Agents
- therapeutic use
- Arthritis
- Rheumatoid
- blood
- drug therapy
- C-Reactive Protein
- metabolism
- Cardiovascular Diseases
- Dose-Response Relationship
- Drug
- Female
- Fibrin Fibrinogen Degradation Products
- metabolism
- Fibrinogen
- metabolism
- Humans
- Male
- Middle Aged
- Plasminogen Activator Inhibitor 1
- blood
- Risk Factors
- Tissue Plasminogen Activator
- blood
- Tumor Necrosis Factor-alpha
- antagonists & inhibitors
- immunology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Clinical and experimental rheumatology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Jin, Tao, 1973
- Bokarewa, Maria, ...
- Amu, Sylvie, 197 ...
- Tarkowski, Andre ...
- Articles in the publication
- Clinical and exp ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
